ARCHIVES

Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.

This article is from The Cancer Letter archive.

Vol. 30 No. 28 | July 9, 2004

Download PDF Visit The Full Archive

Related Articles

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

DCPC advisors OK New Grant Programs In Tobacco, Rural Area

November 12, 1993

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening

April 25, 2014

Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside Of A Registry Trial

July 4, 2014